Omar Elghawy, M., Adam Barsouk, M., Jonathan H. Sussman, B., Benjamin A. Bleiberg, M., Lauren Reed-Guy, M., Christopher D’Avella, M., . . . Lova Sun, M. Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. Elsevier.
Chicago Style (17th ed.) CitationOmar Elghawy, MD, et al. Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. Elsevier.
MLA (9th ed.) CitationOmar Elghawy, MD, et al. Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. Elsevier.